Kindstar Globalgene Technology, Inc. (HKG:9960)

HKG:9960 Revenue

Kindstar Globalgene Technology had revenue of 473.62M CNY in the half year ending June 30, 2026, with 0.06% growth. This brings the company's total for the last twelve months to 950.26M, up 4.29% year-over-year. In the year 2025, Kindstar Globalgene Technology had annual revenue of 933.57M with 0.65% growth. That makes Kindstar Globalgene Technology the 20,141st largest company in the world by revenue and 1,177th in Hong Kong.

• Revenue (ttm): 950.26M CNY
• Revenue Growth: +4.29%
• P/S Ratio: 0.83
• Revenue / Employee: 316.86K CNY
• Employees: 2,999
• Market Cap: 900.42M HKD

Revenue Chart

Chart

Chart

* This company reports financials in CNY.

Revenue by Segment

Chart

• Hematology Testing 563.13M 60.3%
• Neurology Testing 95.05M 10.2%
• Scientific research services and CRO 59.57M 6.4%
• Maternity-Related Testing 50.24M 5.4%
• Oncology Testing 44.80M 4.8%
• Routine Testing 41.28M 4.4%
• Genetic Disease and Rare Diseases 40.94M 4.4%
• Other 38.56M 4.1%

Fiscal year ended Dec 31, 2025 See the full HKG:9960 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	933.57M	6.00M	0.65%
Dec 31, 2024	927.57M	-39.69M	-4.10%
Dec 31, 2023	967.26M	-419.33M	-30.24%
Dec 31, 2022	1.39B	455.92M	48.99%
Dec 31, 2021	930.67M	39.28M	4.41%

Data Source: S&P Global Market Intelligence Last updated: Sep 28, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 17, 2026

Data Sources Report a data error